<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483169</url>
  </required_header>
  <id_info>
    <org_study_id>PICASSO-IMT</org_study_id>
    <nct_id>NCT02483169</nct_id>
  </id_info>
  <brief_title>PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study</brief_title>
  <acronym>PICASSO-IMT</acronym>
  <official_title>Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through this study, the investigators are to prove that Cilostazol effectively prevent
      progression of intima-medial thickness in ischemic stroke patients with high risk of cerebral
      hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side
      effects.

      The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the
      progression of intima-medial thickness compared to aspirin in the ischemic stroke patients
      with symptomatic or asymptomatic old cerebral hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean carotid IMT progression</measure>
    <time_frame>one year</time_frame>
    <description>Annualized rate of change in mean common carotid intimal-medial thickness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum carotid IMT progression</measure>
    <time_frame>one year</time_frame>
    <description>annualized rate of change in maximal carotid intimal-medial thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid plaque score</measure>
    <time_frame>one year</time_frame>
    <description>annualized change of carotid plaque score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Brain Ischemia</condition>
  <condition>Intracranial Hemorrhages</condition>
  <arm_group>
    <arm_group_label>Cilostazol+ Probucol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg cilostazol bid plus probucol plus placebo of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin + Probucol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin plus placebo cilostazol plus probucol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol plus placebo of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin plus placebo of cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>Cilostazol 100mg bid</description>
    <arm_group_label>Cilostazol+ Probucol</arm_group_label>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal produced by Korea Otsuka Pharmaceutical company</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>Probucol 250mg bid</description>
    <arm_group_label>Cilostazol+ Probucol</arm_group_label>
    <arm_group_label>Aspirin + Probucol</arm_group_label>
    <other_name>Probucol is produced by Otsuka Pharmaceutical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 100mg qd</description>
    <arm_group_label>Aspirin + Probucol</arm_group_label>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo of cilostazol</intervention_name>
    <description>same shape and size of active cilostazol</description>
    <arm_group_label>Aspirin + Probucol</arm_group_label>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of aspirin</intervention_name>
    <description>same size and shape of active aspirin 100mg</description>
    <arm_group_label>Cilostazol+ Probucol</arm_group_label>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intima-medial thickness</intervention_name>
    <description>ultrasound measured IMT of both common carotid arteries</description>
    <arm_group_label>Cilostazol+ Probucol</arm_group_label>
    <arm_group_label>Aspirin + Probucol</arm_group_label>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>- Annualized change of mean and maximum common carotid intima-medial thickness</other_name>
    <other_name>- Annualized change of carotid plaque score</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of ischemic stroke within 120 days

          -  Adult aged 20 years or older

          -  High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging
             evidence of previous intracranial hemorrhage)

          -  Informed consent

        Exclusion Criteria:

          -  Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks

          -  Bleeding tendency

          -  Pregnant or breast-feeding woman

          -  Hemorrhagic stroke within 6 months

          -  Patient who was taking antithrombotic medication other than aspirin and does not agree
             to change the previous medication

          -  Severe cardiovascular disease such as cardiomyopathy or congestive heart failure

          -  Life expectancy less than one year

          -  Contraindication to long term aspirin use

          -  Enrolled in other clinical trial within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U Kwon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>December 23, 2015</last_update_submitted>
  <last_update_submitted_qc>December 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sun U. Kwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <keyword>cilostazol</keyword>
  <keyword>probucol</keyword>
  <keyword>intima media thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

